Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study Results

Oishi, Akio; Kojima, Hiroshi; Mandai, Michiko; Honda, Shigeru; Matsuoka, Toshifumi; Oh, Hideyasu; Kita, Mihori; Nagai, Tomoko; Fujihara, Masashi; Bessho, Nobuhiro; Uenishi, Mamoru; Kurimoto, Yasuo; Negi, Akira

doi:10.1016/j.ajo.2013.05.024

Cited by 129 publications

(119 citation statements)

References 50 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…20 In all 17% of eyes in the PDT arm achieved visual gain compared with 30.4% in the ranibizumab arm. The superiority of ranibizumab in PCV in terms of visual outcome was proved, but the effectiveness of combined treatment was not evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…The superiority of ranibizumab in PCV in terms of visual outcome was proved, but the effectiveness of combined treatment was not evaluated. 20 The EVEREST study was the only randomized study comparing the three arms for PCV, including ranibizumab, PDT, and combined therapy. 15 The study concluded that PDT was more effective than ranibizumab in causing regression of polyps, with the mean gain in visual acuity being similar among the three groups.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Young

et al. 2014

Eye

View full text Add to dashboard Cite

Aim To report the visual outcome of polypoidal choroidal vasculopathy receiving combined treatment with photodynamic therapy using Visudyne and intravitreal ranibizumab injections, and to analyze the predictive factors of visual outcome at 1 year post treatment. Methods Seventy-four consecutive patients with newly diagnosed polypoidal choroidal vasculopathy were treated with photodynamic therapy using Visudyne and three loading doses of intravitreal ranibizumab. The final visual outcome and polyp eradication rate at 1 year were reported. A stepwise regression model was used to estimate the baseline clinical factors predictive of better visual outcome and polyp eradication.Results Visual acuities at 12-months followup improved significantly compared with baseline from 0.828 logMAR to 0.728 logMAR (P ¼ 0.026). The mean foveal thickness decreased from 380±175 to 278±117 mm. In all 29.7% of eyes improved at least by 0.3 logMAR, and 55.4% remained stable in visual acuity with less than 0.3 logMAR change. Overall, 85% of eyes achieved at least stable vision, 20.2% (15/74) cases achieved polyp eradication on angiogram, and 60.8% (45/74) achieved polyp size reduction on angiogram at 1 year. Regarding predictive factors, the baseline visual acuity (P ¼ 0.003), no foveal involvement by abnormal choroidal vasculature (Po0.0001), absence of hard exudates (0.001) or subretinal fluid (o0.0001) are important clinical factors affecting the final visual outcome. Conclusions Combination therapy with photodynamic therapy using Visudyne and three loading doses of intravitreal ranibizumab injections resulted in 85% success rate on visual stabilization and 81% success rate in polypoidal lesion control.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Young

et al. 2014

Eye

View full text Add to dashboard Cite

show abstract

“…However, Song et al [141] reported that IVR without PDT for PCV in Korean patients resulted in significant visual and anatomical improvements over a 1-year follow-up period, and other reports suggested that the disappearance of the polypoidal lesions occurred at a high rate in PCV cases after anti-VEGF monotherapy [74,142,143]. A recent review suggested an overall improvement of the VA of PCV patients using IVR [144], and a most recent multicenter randomized controlled trial (LAPTOP study) revealed that IVR monotherapy achieved a significantly better visual prognosis than PDT monotherapy in PCV patients [145]. However, Matsumiya et al [16,17] reported that the degree of improvement in the VA in PCV patients was lower than that of tAMD patients treated by anti-VEGF monotherapy.…”

Section: Response To Treatmentmentioning

confidence: 99%

Polypoidal Choroidal Vasculopathy: Clinical Features and Genetic Predisposition

2013

Self Cite

View full text Add to dashboard Cite

Polypoidal choroidal vasculopathy (PCV) is currently recognized as a phenotype of age-related macular degeneration (AMD). PCV is believed to be a type of choroidal neovascularization, although some cases of PCV show a distinct vascular abnormality of the choroidal vessels. PCV often shows several unique clinical manifestations which are apparently different from typical neovascular AMD (tAMD). In addition, the natural course and response to treatment are often different between tAMD and PCV. Moreover, recent genetic studies suggested a possible difference in the genetic susceptibility to disease between tAMD and PCV, as well as the existence of heterogeneity among PCV cases. In viewing the accumulation of knowledge about PCV, we have summarized the recent literature regarding PCV in this review article to improve the understanding of this clinical entity including possible susceptibility genes. We will also discuss the optimal treatment strategies for PCV in accordance with the results of recent clinical and genetic studies.

show abstract

“…In the treatment of PCV, several studies report that anti-VEGF therapy improves visual acuity and structural outcomes. Oishi et al [19] showed that intravitreal ranibizumab therapy was more effective than PDT in the management of PCV. Kokame et al [20] found that monthly intravitreal ranibizumab administration improved vision and facilitated the resolution of subretinal lesions.…”

Section: Discussionmentioning

confidence: 99%

Comparing Ranibizumab and Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy

Song

Cho

Kim

et al. 2018

J Retin

View full text Add to dashboard Cite

Purpose:To compare the clinical efficacy of intravitreal ranibizumab and aflibercept in treatment-naïve patients with polypoidal choroidal vasculopathy (PCV). Methods: We retrospectively analyzed the medical records of 82 eyes with treatment-naïve PCV who were treated with ranibizumab or aflibercept and followed for at least six months. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) as measured by optical coherence tomography (OCT), and polyp size in indocyanine green angiography (ICGA) were used for evaluation. The primary endpoint was change at 12 months relative to baseline with respect to BCVA and CFT. Secondary endpoints were anatomical changes in OCT and ICGA findings from baseline. Results: Data from 46 eyes were considered for the primary endpoint. Twenty-five and 21 eyes received ranibizumab and aflibercept, respectively. Statistically significant improvements in BCVA and CFT compared with baseline were noted in both groups. Of 82 eyes assessed for secondary endpoints, 52 and 30 received ranibizumab and aflibercept, respectively. The subretinal fluid , pigment epithelial detachment , and subfoveal thickness decreased significantly throughout the follow-up in each group. Polyp regression was found in 37.5% and 32.4% of the ranibizumab-and aflibercept-treated groups, respectively. However, there was no significant difference in the treatment results between the drugs. Conclusions: In a comparison of the clinical efficacy of intravitreal ranibizumab and that of aflibercept in patients with PCV, the treatment groups showed similar clinical results in terms of functional and anatomical outcomes after 12 months.

show abstract

Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study Results

Cited by 129 publications

References 50 publications

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Polypoidal Choroidal Vasculopathy: Clinical Features and Genetic Predisposition

Comparing Ranibizumab and Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy

Contact Info

Product

Resources

About